Immunoglobulin A IgA Vasculitis Market Growth Potential: What The Latest Forecast Reveals

Immunoglobulin A IgA Vasculitis Market Report

Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.

Immunoglobulin A IgA Vasculitis Market Revenue Outlook: What CAGR Lies Ahead Through 2030?

The market for immunoglobulin A (IgA) vasculitis has experienced robust expansion over recent years. Projections indicate its expansion from $1.63 billion in 2025 to $1.74 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 6.5%. Historically, this expansion has been driven by factors such as enhanced clinical comprehension of IgA-mediated autoimmune conditions, a rise in the diagnosis of pediatric vasculitis incidents, more widespread application of corticosteroids and immunosuppressive medications, the expansion of hospital-centric autoimmune treatment services, and growing expertise in nephrology.

The market for immunoglobulin a iga vasculitis is projected to experience substantial expansion over the upcoming years. This market is forecast to reach $2.21 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.2%. Key drivers for this growth during the forecast period include increasing research efforts into new immunomodulatory drugs, the rising embrace of personalized autoimmune treatments, a heightened emphasis on protecting renal function long-term, the expansion of pipelines for biologic treatments, and advancements in diagnostic imaging and biopsy methods. Significant trends anticipated in the forecast period encompass an intensified focus on diagnosing the disease early and accurately, the growing uptake of targeted immunosuppressive therapies, wider utilization of biomarker-based disease monitoring, the broadening of personalized treatment strategies, and a stronger emphasis on managing renal outcomes.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=66856683&type=smp&name=Immunoglobulin%20A%20IgA%20Vasculitis%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Immunoglobulin A IgA Vasculitis Market Expansion Drivers: What’s Shaping Future Growth?

The increasing occurrence of autoimmune conditions is projected to fuel the expansion of the immunoglobulin A (IgA) vasculitis market in the future. These conditions involve the body’s immune system erroneously targeting its own healthy cells, tissues, or organs, rather than defending against infections and external threats. The growing prevalence of autoimmune disorders is mainly attributed to increased exposure to environmental pollutants, which can upset immune system regulation and provoke irregular reactions. Immunoglobulin A (IgA) vasculitis plays a role in autoimmune diseases by initiating an immune reaction resulting in inflammation within small blood vessels, thereby assisting in the comprehension and potential therapeutic approaches for diverse autoimmune conditions. For example, data from February 2024, provided by the Vasculitis Foundation, a US-based non-profit, indicates an annual incidence of IgA vasculitis in U.S. adults of approximately 2 cases per 100,000, although global rates show significant variability, spanning from around 60 to 550 cases per million. Consequently, the escalating incidence of autoimmune diseases is a key driver for the growth of the immunoglobulin A (IgA) vasculitis market.

Immunoglobulin A IgA Vasculitis Market Segment Outlook: Which Categories Are Growing Fastest?

The immunoglobulin a iga vasculitis market covered in this report is segmented –

1) By Treatment Type: Medications, Plasma Exchange, Supportive Care, Immunosuppressive Therapy

2) By Diagnosis Method: Blood Tests, Urinalysis, Imaging Studies, Biopsy

3) By Route Of Administration: Oral, Injectables

4) By End User: Hospitals, Specialty Clinics, Homecare Settings

Subsegments:

1) By Medications: Corticosteroids, Immunosuppressants, Cyclophosphamide, Azathioprine, Mycophenolate Mofetil

2) By Plasma Exchange: Therapeutic Plasma Exchange, Plasma Filtration

3) By Supportive Care: Pain Management, Kidney Function Support, Blood Pressure Management

4) By Immunosuppressive Therapy: Methotrexate, Rituximab

Immunoglobulin A IgA Vasculitis Market Strategic Trends: What Defines The Next Growth Phase?

Leading companies operating within the immunoglobulin A (IgA) vasculitis market are concentrating on developing innovative therapies, such as targeted biologics and immunomodulators, to alleviate inflammation and prevent renal complications. These targeted biologics and immunomodulators are advanced treatments that modulate specific immune pathways to reduce inflammation and prevent immune-mediated damage in IgA vasculitis. For instance, in April 2025, Novartis AG, a Switzerland-based pharmaceutical company, obtained approval from the U.S. Food and Drug Administration (FDA) for Vanrafia (atrasentan) for the treatment of primary immunoglobulin A nephropathy (IgAN). Vanrafia is a once-daily, oral, selective endothelin A receptor antagonist designed to reduce proteinuria in adults with primary IgAN who are at risk of rapid disease progression. It can be integrated into existing supportive care regimens without requiring a risk evaluation and mitigation strategy (REMS).

Immunoglobulin A IgA Vasculitis Market Leading Companies And Competitive Benchmarking

Major companies operating in the immunoglobulin a iga vasculitis market are Pfizer Inc, F. Hoffmann-La Roche Ltd, Novartis AG, Takeda Pharmaceutical Company Limited, Amgen Inc, Intas Pharmaceuticals Ltd, Zydus Lifesciences Limited, Biogen Inc, Chugai Pharmaceutical Co Ltd, CSL Behring, AbbVie Inc, Johnson & Johnson, Bristol-Myers Squibb Company, UCB SA, Sanofi, GSK plc, Astellas Pharma Inc, Teva Pharmaceuticals USA Inc, Chinook Therapeutics, Guangdong Hengrui Pharmaceutical Co Ltd, Visterra Inc, Selecta Biosciences, Jiangsu HengRui Medicine Co Ltd, Travere Therapeutics Inc, Everest Medicines Ltd

View The Full Immunoglobulin A IgA Vasculitis Market Report:

https://thebusinessresearchcompany.com/report/immunoglobulin-a-iga-vasculitis-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Immunoglobulin A IgA Vasculitis Market Top Region: Where Does Most Revenue Come From?

North America was the largest region in the immunoglobulin A (IgA) vasculitis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the immunoglobulin a iga vasculitis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model